Spotlight On... Michael J. Fox Foundation signs up for wearable-enabled Phase III trial project; Thermo Fisher inks $1.3B Affymetrix deal; Guardant Health unveils $100M Series D round; and more...

The Michael J. Fox Foundation (MJFF) has furthered its drive to establish wearable devices as part of the data-gathering toolkit in clinical trials of Parkinson's treatments. Cynapsus is collaborating with MJFF on the inclusion of a wearable-enabled substudy in its Phase III trial. The alliance builds on a deal MJFF struck with Intel in 2014, which set out to improve the monitoring of Parkinson's patients between site visits through the use of wearable devices. Release

> Thermo Fisher Scientific agreed to buy genomics veteran Affymetrix for $1.3 billion. Release

> Guardant Health wrapped up the first closing of a $100 million round intended to bankroll the expansion of its sequencing platform. News

> Illumina set up a new company to develop a blood-based screening test for cancer. Statement

> Validic added a way to import data from nonconnected devices to its digital health platform. More

> PierianDx raised $9.25 million to expand the capabilities of its genomics software. Item | More

> NSF committed $10 million to support the creation of a set of guidelines for synthetic biology. Post

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.